Alvotech enters into commercialization agreement with polifarma for proposed biosimilar to eylea® (aflibercept)

Alvotech (nasdaq: alvo), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that it has entered into an exclusive agreement with polifarma ilac san. ve tic. a.s. (“polifarma”) for the commercialization in turkey of avt06, a proposed biosimilar to eylea® (aflibercept).
ALVO Ratings Summary
ALVO Quant Ranking